Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Lymphoma and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3290
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Lymphoma and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Peptides.

    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
4SC
7TM Pharma
A&G Pharmaceutical
Abbott
Abiogen
Acceleron Pharma
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Allostera
Allosterix
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Axelar
Baxter International
Bayer
Benitec
Betapharma
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
BioLineRx
BioNumerik
BioSante
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiasma
Chong Kun Dang
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
CLL Pharma
Compugen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
Digna Biotech
Dong-A
Dongkook Pharm
Dr Reddy’s
Dynavax Technologies
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Esperance Pharmaceuticals
Exelixis
Favrille
Forma Therapeutics
Formula Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
GP Pharm
Gradalis
Gryphon Therapeutics
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Karyon-CTT
Kiadis
Kinex
Kirax
Kissei
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
NewSouth Innovations
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
Novartis
Noxxon
NPS Pharmaceuticals
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
OXiGENE
Paladin Labs
PanaGin
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Pro-Pharmaceuticals
Progen Pharmaceuticals
ProNAi Therapeutics
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBIO
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Serometrix
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Soligenix
Spectrum Pharmaceuticals
SRI International
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
Unigene
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Wyeth
XBiotech
Xencor
Xerion
Xigen
Xoma
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zenotech
Zensun
Zenyaku Kogyo
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEZS-108
afamelanotide
afatinib
aflibercept
alemtuzumab
amrubicin hydrochloride
angiopep+paclitaxel
ARQ-197
astuprotimut-r
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
bexarotene
BIBF-1120
bortezomib
brentuximab vedotin
canfosfamide hydrochloride
CBP-501
celecoxib
cetuximab
cladribine
corticorelin acetate
crizotinib
dacomitinib
denileukin diftitox
deslorelin
docetaxel
E-75
elliptinium acetate
emepepimut-S
endostatin
enzastaurin hydrochloride
EP-100
epirubicin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
FPI-01
galiximab
gefitinib
goserelin
GV-1001
GX-301
HBP-347
Her-2/Neu peptides
histrelin
ibritumomab tiuxetan
icotinib hydrochloride
imMucin
iniparib
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon (gamma1b)
interferon alfa-2b
interferon alpha-2b
IPP-204106
irinotecan hydrochloride
ISA-P53-01
kahalalide F
lanreotide
lapatinib ditosylate
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
MDX-1379
mitoxantrone
motesanib diphosphate
nadroparin
NAFB001
necitumumab
netupitant
nimotuzumab
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
pemetrexed disodium
pixantrone
plitidepsin
polyclonal antibody stimulator
pralatrexate
ramucirumab
razoxane
Reditux
rhIFN-alpha
rindopepimut
rituximab
romidepsin
romurtide
sobuzoxane
sorafenib tosylate
sotatercept
Survivac
talactoferrin alfa
tegafur + uracil
temsirolimus
teniposide
thymalfasin
TM-30339
topotecan
TS-1
vapreotide, immediate-release
vitespen
VX-001
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Peptides.
    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Prostate Cancer, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Triple Analysis: Lung Cancer, Melanoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Biologicals in Oncology Drug Pipeline Update
BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More